Equities

Net Medical Xpress Solutions Inc

NMXS:PKL

Net Medical Xpress Solutions Inc

Actions
  • Price (USD)0.0122
  • Today's Change0.00 / 0.00%
  • Shares traded55.00
  • 1 Year change--
  • Beta-0.6726
Data delayed at least 15 minutes, as of Sep 20 2024 19:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Net Medical Xpress Solutions Inc's revenues fell -27.88% from 4.22m to 3.05m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 151.00k to a loss of 344.00k.
Gross margin25.77%
Net profit margin-11.33%
Operating margin-10.96%
Return on assets-34.26%
Return on equity-91.27%
Return on investment-90.58%
More ▼

Cash flow in USDView more

In 2016, cash reserves at Net Medical Xpress Solutions Inc fell by 103.00k. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 80.00k for operations while cash used for financing totalled 23.00k.
Cash flow per share-0.0152
Price/Cash flow per share--
Book value per share0.0098
Tangible book value per share0.0018
More ▼

Balance sheet in USDView more

Net Medical Xpress Solutions Inc has a Debt to Total Capital ratio of 25.86%.
Current ratio1.05
Quick ratio1.02
Total debt/total equity0.3487
Total debt/total capital0.2586
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -339.78%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-17.75
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.